Exousia Bio (LMMY) Common Equity (2022 - 2025)

Exousia Bio has disclosed Common Equity across 4 years of filings, most recently posting $21.8 million for Q4 2025.

• Common Equity for Q4 2025 came in at $21.8 million, up 87570.58% year-over-year; the trailing twelve-month figure through Nov 2025 was $21.8 million (up 87570.58% YoY), and the FY2024 annual result was -$54895.0, down 88.72% from the prior year.
• Common Equity came in at $21.8 million for Q4 2025 at Exousia Bio, up from -$35314.0 in the prior quarter.
• In the past five years, Common Equity ranged from a high of $21.8 million in Q4 2025 to a low of -$58805.0 in Q3 2024.
• The 4-year median for Common Equity is -$29088.0 (2023), against an average of $1.6 million.
• Across the five-year window, Common Equity slumped 6556.29% in 2023 and jumped 87570.58% in 2025, its largest moves.
• Exousia Bio's Common Equity stood at -$21814.0 in 2022, then tumbled by 105.47% to -$44822.0 in 2023, then jumped by 155.45% to $24854.0 in 2024, then surged by 87570.58% to $21.8 million in 2025.
• The last three Common Equity figures came in at $21.8 million (Q4 2025), -$35314.0 (Q3 2025), and $24854.0 (Q4 2024), per Business Quant data.